Navigation Links
New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures

nal formulation demonstrated fewer daily fluctuations in serum concentration and more stable blood levels over time."

ABOUT THE ARMOR STUDY

In the ARMOR study, patients naive to Lamictal, thirteen years of age or older with uncontrolled partial seizures, taking a stable regimen of 1 or 2 AEDs were enrolled in an 8 week baseline phase. Patients having 8 or more partial seizures were randomized to receive either once daily Lamictal XR or placebo. The treatment period consisted of escalation (7 weeks) and maintenance phases (12 weeks) with dosing based on background AEDs. The primary endpoint was percentage change from baseline in weekly partial seizures during the entire treatment phase.

Of 326 patients enrolled, 236 were randomized and included in the intent- to-treat population (116 Lamictal XR, 120 placebo). The median percent decrease from baseline in all partial seizures was 46 percent compared to 24 percent for placebo during the entire treatment phase, 28 percent compared to 16 percent during the escalation phase of treatment and 58 percent compared to 27 percent during the maintenance phase of treatment.

Time to greater than or equal to 50 percent reduction in seizure frequency was analyzed using a two sided log-rank statistic. In patients taking Lamictal XR, 42 percent achieved greater than or equal to 50 percent reduction in seizure frequency at the end of the treatment period. The time to achieve and maintain greater than or equal to 50 percent reduction in seizure frequency with Lamictal XR was reached at day 18. During the 12-week maintenance period, the percent of patients with 100 percent decrease from baseline partial seizures were 19 percent and 5 percent (Lamictal XR vs. placebo).

The most common (>5 percent) drug-related adverse events for Lamictal XR and placebo, respectively, were dizziness, 18 vs. 5 percent, headache, 17 vs. 15 percent, somnolence, 7 vs. 4 percent, nausea, 7 vs. 2 percent, and diarrhea, 7 vs. 4
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:9/14/2014)... 2014  Abbott announced today positive one-year clinical ... randomized, controlled trial comparing the safety and effectiveness ... market-leading metallic XIENCE family of DES.  The trial, ... included 501 people with coronary artery disease (CAD), ... results were featured at a late-breaking session at ...
(Date:9/12/2014)... Colorado eye care provider Vision Care Specialists announced expansion ... high quality eye care services. Photo - http://photos.prnewswire.com/prnh/20140912/145684 ... locations in Aurora , Lakewood ... days a week. Hours are Monday, Tuesday, Thursday and Friday 7:45 ... Saturday 7:45 AM to 2:30 PM. The downtown Denver ...
(Date:9/12/2014)...   Synthetic Biologics, Inc. (NYSE MKT: ... and drug programs targeting specific pathogens that cause ... U.S. Food and Drug Administration (FDA) has granted ... monoclonal antibody (mAb) combination for the treatment of ... the U.S., Orphan Drug Designation provides a variety ...
Breaking Medicine Technology:ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 2ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 3ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 4ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent 5Colorado Eye Care: Vision Care Specialists Expands Hours, adds Optometrists to Denver Locations 2Colorado Eye Care: Vision Care Specialists Expands Hours, adds Optometrists to Denver Locations 3Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis) 2Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis) 3
... and Efficacy Data Reported ... Enrollment Advancing Ahead of Schedule, SOUTH SAN FRANCISCO, ... ) today presented an update of interim,data from the ... product,candidate, voreloxin (formerly SNS-595), in platinum-resistant ovarian,cancer patients at ...
... Results Confirm Previously Demonstrated Survival Advantages of Tarceva in ... This Difficult-to-Treat Disease ... - ABSTRACT No: 4507, ... Tarceva (erlotinib) and chemotherapy significantly,improves the time patients with metastatic pancreatic cancer ...
Cached Medicine Technology:Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 2Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 3Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 4Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting 5Patients with Pancreatic Cancer Can Benefit From Avastin(R) Plus Tarceva(R) 2Patients with Pancreatic Cancer Can Benefit From Avastin(R) Plus Tarceva(R) 3
(Date:9/15/2014)... (PRWEB) September 15, 2014 Insurers ... initiatives that bring providers on board as partners ... satisfaction. When bundled payment programs are designed properly ... incentives, incentivize hospitals to work collaboratively with providers, ... tally. On Sept. 24, the Atlantic Information Services ...
(Date:9/15/2014)... New Jersey, Sept 9, 2014 – New Jersey ... firm of Ricci Tyrrell Johnson & Grey, PLLC, has ... No. 8,774,911 from the United States Patent and Trademark ... locator instrument is invented by Dr. Lee M. Buono ... in minimally-invasive spine surgery. , Precise pedicle location is ...
(Date:9/15/2014)... September 15, 2014 Recently, Top10BestSEOHosting.com ... announced that GreenGeeks ( http://www.greengeeks.com/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), IX Web ... suppliers in 2014. , “These companies have outperformed ... customer support, so that we call them the ... people can get the best web hosting to ...
(Date:9/14/2014)... 14, 2014 When active, the protein ... several human cancers including pancreatic, prostate, lung, colon and ... available. A study published today in the journal Nature ... these Ral proteins: "When you want to keep an ... shut. We took another approach – we put a ...
(Date:9/14/2014)... -- Getting enough sleep each night may mean you,re less likely ... study suggests. The study included more than 3,700 people in ... of seven years. Those who slept less than six hours ... to have extended absences from work due to illness, the investigators ... work due to sickness were those who slept between seven and ...
Breaking Medicine News(10 mins):Health News:Sept. 24 Webinar to Profile Geisinger Health System, BCBS of North Carolina’s Successful Bundled-Payment Programs 2Health News:Patent Attorney Stuart M. Goldstein Helps Client Receive a Patent on a Surgical Device designed to Increase Accuracy and Safety in Vertebrae Repair and Attachment 2Health News:Patent Attorney Stuart M. Goldstein Helps Client Receive a Patent on a Surgical Device designed to Increase Accuracy and Safety in Vertebrae Repair and Attachment 3Health News:Patent Attorney Stuart M. Goldstein Helps Client Receive a Patent on a Surgical Device designed to Increase Accuracy and Safety in Vertebrae Repair and Attachment 4Health News:Patent Attorney Stuart M. Goldstein Helps Client Receive a Patent on a Surgical Device designed to Increase Accuracy and Safety in Vertebrae Repair and Attachment 5Health News:Nature: New drug blocks gene driving cancer growth 2Health News:Nature: New drug blocks gene driving cancer growth 3Health News:A Good Night's Sleep May Mean a Good Day's Work 2
... 57 million Americans currently living with "pre-diabetes" could benefit from ... a new study published in this month,s American Journal ... Weight Watchers group program, overweight or obese adults who attended ... lost weight, but also significantly reduced fasting glucose and insulin ...
... Georgia Institute of Technology has received a $100,000 Grand ... Foundation. The grant will support an innovative global health ... in Georgia Tech,s School of Mechanical Engineering, titled "Complement-based ... grants announced by the Gates Foundation in the fourth ...
... successful testing of a sensor that can instantly tell whether ... by emergency room doctors to determine whether a patient has ... diabetics do not take enough insulin. Someday the technology may ... determine whether they need more insulin. A report on the ...
... Through ... and rare diseases are possible before they ever manifest. The future of medicine starts ... (PRWEB) ... world’s first predictive medicine company, is working with healthcare providers to PREDICT, PREVENT, and ...
... ... ... -- IT-Lifeline, the Northwest’s foremost provider of disaster recovery and business continuity solutions, and ... have entered into a joint marketing agreement to provide a suite of Disaster Recovery ...
... fingerroot inhibited production of carcinogenic compounds , THURSDAY, May ... to your burgers before tossing them on the grill ... of the meat, but they can also cut the ... beef. , Scientists at Kansas State University (KSU) found ...
Cached Medicine News:Health News:New study finds attending Weight Watchers meetings helps reduce the risk for type 2 diabetes 2Health News:Georgia Tech awarded Gates Foundation grant for innovative global health research 2Health News:Existence Genetics is Pioneering the Field of Predictive Medicine - Nexus Technologies Critical in Understanding and Preventing Deadly Disease 2Health News:Existence Genetics is Pioneering the Field of Predictive Medicine - Nexus Technologies Critical in Understanding and Preventing Deadly Disease 3Health News:IT-Lifeline, Inc and OptiStor Technologies, Inc. Enter Joint Marketing Agreement 2Health News:IT-Lifeline, Inc and OptiStor Technologies, Inc. Enter Joint Marketing Agreement 3Health News:Some Spices Cut Cancer Risk That Comes With Grilled Burgers 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: